Valsartan And Hydrochlorothiazide Tablet, Film Coated
Product Images NDC 51655-243

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Valsartan And Hydrochlorothiazide (NDC 51655-243). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northwind Health Company, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Label (51655 243 52)

Label (51655 243 52)
NDC 51655-243-52 is for a drug called Valsartan and Hydrochlorothiazide, which is available in the form of tablets. Each film-coated tablet contains USP 320mg of Valsartan and USP 25mg of Hydrochlorothiazide. The package contains 30 tablets and it is Rx only, meaning it requires a prescription to purchase. The dosage and storage instructions can be found in the package insert. The tablets should be stored in the original container at a temperature between 20° - 25°C (68° - 77°F) and should be protected from moisture and heat. The drug should be kept out of the reach of children. The tablets have been repackaged by Northwind Pharmaceuticals from the original product labeled as 0378-6325-XX manufactured by Mylan Pharmaceuticals Inc. The GTIN code for this drug is 0351655243527, and the provided LOT number is 0000000000. The expiration date mentioned is 00/00/0000, which implies that this information is not available.*
FDA Label Image

Figure 1: Probability Of Achieving Systolic Blood Pressure Less Than 140 Mmhg At Week 8 (Image 01)

Figure 1: Probability Of Achieving Systolic Blood Pressure Less Than 140 Mmhg At Week 8 (Image 01)
This appears to be a graph showing blood pressure readings (SBP - systolic blood pressure) below 140 mmHg, recorded before and after treatment with hydrochlorothiazide 25 mg. The graph also shows a baseline SBP range from 100 to 180 mmHg.*
FDA Label Image

Figure 2: Probability Of Achieving Diastolic Blood Pressure Less Than 90 Mmhg At Week 8 (Image 02)

Figure 2: Probability Of Achieving Diastolic Blood Pressure Less Than 90 Mmhg At Week 8 (Image 02)
FDA Label Image

Figure 3: Probability Of Achieving Systolic Blood Pressure Less Than 130 Mmhg At Week 8 (Image 03)

Figure 3: Probability Of Achieving Systolic Blood Pressure Less Than 130 Mmhg At Week 8 (Image 03)
FDA Label Image

Figure 4: Probability Of Achieving Diastolic Blood Pressure Less Than 80 Mmhg At Week 8 (Image 04)

Figure 4: Probability Of Achieving Diastolic Blood Pressure Less Than 80 Mmhg At Week 8 (Image 04)
This text appears to be a list of medication dosages and medical measurements, including blood pressure and medication names. It is not clear what the context of the list is or what it is intended to be used for, but it may be related to a study or clinical trial.*
FDA Label Image

Valsartan Structural Formula (Image 05)

Valsartan Structural Formula (Image 05)
FDA Label Image

Hydrochlorothiazide Structural Formula (Image 06)

Hydrochlorothiazide Structural Formula (Image 06)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.